- MRG1061 is Micregen’s first product targeting neonatal conditions. It is a multipotent stem cell-derived, cell-free injectable Secretomix, designed to aid tissue regeneration
Micregen has an innovative pipeline to tackle some of the most devastating and life-changing health problems in neonates, infants and adults using allogeneic stem cell derived Secretomix.
Micregen’s pipeline of therapeutics aim to impact on a range of diseases and illness from neonates through to those that effect the elderly and infirm. Building on research spanning decades, Micregen is focused on translating this innovation from the laboratory to the clinic.
Micregen aim to make a significant impact on global health by offering first in class treatment options across a wide range of multiple inflammatory and degenerative conditions.
Micregen have two allogeneic products in pre-clinical development: